Advanced digestive neuroendocrine tumors: Metastatic pattern is an independent factor affecting clinical outcome

Pancreas

Volumn 43, Issue 2, 2014, Pages 212-218

  Panzuto, Francesco ^a   Merola, Elettra ^a   Rinzivillo, Maria ^a   Partelli, Stefano ^b,c   Campana, Davide ^d   Iannicelli, Elsa ^e   Pilozzi, Emanuela ^f   Mercantini, Paolo ^a   Rossi, Michele ^e   Capurso, Gabriele ^a   Scarpa, Aldo ^g   Cascinu, Stefano ^b   Tomassetti, Paola ^d   Falconi, Massimo ^b,c   Fave, Gianfranco Delle ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Radiology   (United States)

^f United Pathology   (United States)

^g UNIVERSITY OF VERONA   (Italy)

Author keywords

carcinoids; metastases; neuroendocrine tumors; pancreatic endocrine tumors; staging

Indexed keywords

AGED; DIGESTIVE SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84894436231     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000032     Document Type: Article

References (25)

1. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society Classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909-918.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
3. Kuiper P, Verspaget HW, van Slooten HJ, et al. Pathological incidence of duodenopancreatic neuroendocrine tumors in the Netherlands: a Pathologisch Anatomisch Landelijk Geautomatiseerd Archief Study. Pancreas. 2010;39:1134-1139.
4. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083-1092.
5. Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764-777.
6. Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332-3341.
7. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
8. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762.
9. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
10. Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16:585-597.
11. Frilling A, Li J, Malamutmann E, et al. Treatment of liver metastases from neuroendocrine tumors in relation to the extent of hepatic disease. Br J Surg. 2009;96:175-184.
12. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471-476.
13. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885-894
14. Panzuto F, Campana D, Fazio N, et al. Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology. 2012;96:32-40.
15. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372-2377.
16. Bosman F, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010.
17. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824-833.
18. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152-160.
19. Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer Staging Classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420-425.
20. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol. 2011;29:934-943.
21. Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724-764.
22. Vinik AI, Anthony L, Boudreaux JP, et al. Neuroendocrine tumors: a critical appraisal of management strategies. Pancreas. 2010;39:801.20-818.20.
23. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656-4663.
24. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
25. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 501-513.